The Korea Herald · All News

Wegovy seeks insurance edge in Korea's obesity drug war

· By Kan Hyeong-woo
Story summary

Competition in Korea's obesity drug market is intensifying. Novo Nordisk seeks national health insurance coverage for Wegovy, aiming to regain ground against Eli Lilly's market-leading Mounjaro before Hanmi Pharmaceutical launches its newly approved homegrown rival, Eppe. Novo Nordisk Korea applied to the Health Ins…

Read at The Korea Herald

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.

Your local edition.

Choose a timezone for story timestamps and date filters.